|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States. |
| 公司地址
| 31 East 62nd Street, New York, NY, USA, 10065 |
| 電話號碼
| +1 212 672-9100 |
| 傳真號碼
| +1 212 697-3130 |
| 公司網頁
| https://www.siga.com |
| 員工數量
| 46 |
| Dr. Diem Nguyen, M.B.A.,PhD |
Chief Executive Officer and Director |
美元 835.38K |
28/04/2025 |
| Mr. Daniel J. Luckshire |
Executive Vice President, Chief Financial Officer and Corporate Secretary |
美元 730.34K |
28/04/2025 |
| Dr. Dennis E. Hruby,PhD |
Executive Vice President and Chief Scientific Officer |
美元 726.72K |
28/04/2025 |
| Mr. Lawrence R. Miller |
General Counsel and Corporate Secretary |
美元 520.31K |
28/04/2025 |
|
|
| Mr. Harold E. Ford, Jr |
Independent Director |
28/04/2025 |
| Dr. Holly L. Phillips, M.D. |
Independent Director |
28/04/2025 |
| Dr. Gary J. Nabel, M.D.,PhD |
Independent Director |
28/04/2025 |
| Mr. Julian Nemirovsky |
Independent Director |
28/04/2025 |
| Dr. Diem Nguyen, M.B.A.,PhD |
Chief Executive Officer and Director |
28/04/2025 |
| Mr. Joseph W. Marshall, III |
Independent Director |
28/04/2025 |
| Mr. Jaymie A. Durnan |
Independent Director |
28/04/2025 |
| General John M. Keane, (Ret.) |
Independent Director |
18/03/2025 |
|
|
|
|
